R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the
efficacy and safety of R-CHOP (Rituximab-Cyclophosphamide, Epirubicin, Vincristine and
Prednisone) combined with lenalidomide in the first-line treatment for patients with medium
to high risk/high risk diffuse large B cell lymphoma.